Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Short chain polypeptide capable of inhibiting binding of MD2 and CIRP protein and application of short chain polypeptide

A TAT-CIRP, short peptide technology, applied in the field of biomedicine, to achieve the effect of inhibiting cell death, increasing membrane penetration efficiency, and low synthesis cost

Inactive Publication Date: 2018-11-23
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF10 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether MD2 mediates central nervous system damage, stroke damage, and therapeutic measures targeting MD2 have not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Short chain polypeptide capable of inhibiting binding of MD2 and CIRP protein and application of short chain polypeptide
  • Short chain polypeptide capable of inhibiting binding of MD2 and CIRP protein and application of short chain polypeptide
  • Short chain polypeptide capable of inhibiting binding of MD2 and CIRP protein and application of short chain polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] The present invention will be further described in detail below in conjunction with specific embodiments, which are explanations of the present invention rather than limitations.

[0027] 1. Chemical synthesis of TAT-CIRP short peptide

[0028] Design purpose and requirements: In order to reduce the molecular weight of the target peptide and increase the penetration efficiency of the membrane-penetrating peptide, a part of the sequence truncated from the CIRP protein is selected as the binding peptide, and the truncated amino acid sequence must also maintain a high ability to bind MD2 It is required that it can be used as a false substrate to prevent the combination of CIRP and MD2, thereby inhibiting the activity of MD2, and then inhibiting the inflammatory response, apoptosis and necroptosis mediated by the MD2-TLR4 signaling pathway.

[0029] The membrane-penetrating peptide TAT used in the present invention has only 11 amino acids, which can effectively introduce bi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses short chain polypeptide capable of inhibiting the binding of MD2 and CIRP protein and application of the short chain polypeptide and belongs to the technical field of biomedicines. The short chain polypeptide disclosed by the invention is fusion peptide based on a cell-penetrating peptide TAT sequence and a CIRP protein and MD2 protein binding sequence. A nucleotide sequence is shown as SEQ ID NO. 3. An experiment proves that the synthesized fusion peptide can be used for regulating and controlling the function of MD2. Therefore, the invention discloses the applicationof the short chain polypeptide to simultaneous inhibition of inflammatory response, apoptosis and necroptosis and a new treatment target spot for promoting wound repairing.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to a short peptide for inhibiting the combination of MD2 and CIRP protein and application thereof. Background technique [0002] At present, the prognosis of stroke patients is not optimistic. Once a stroke occurs, the 1-month mortality rate is 25%, the 6-month mortality rate is 33.3%, and the 1-year mortality rate rises to 50%. The prognosis of hemorrhagic stroke is even more severe, and its 1-month mortality rate is as high as 50%. Because ischemic and hemorrhagic strokes are treated very differently, it is important to distinguish between stroke types clinically. However, distinguishing stroke types depends on CT and MRI (magnetic resonance imaging) results. These imaging examination results often take tens of minutes or even hours, which may lead to missing the golden treatment time for treating patients. For ischemic stroke, currently the only FDA-approved dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/10A61K47/64A61P9/10A61P25/28
CPCC07K7/08A61K38/00A61K47/64A61P9/10A61P25/28C07K2319/10
Inventor 方宗平熊利泽董海龙冯云邓姣杨谦梓白福海李雨衡
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com